

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): August 5, 2019**

**INSULET CORPORATION**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware  
(State or Other Jurisdiction  
of Incorporation)**

**001-33462  
(Commission  
File Number)  
100 Nagog Park,  
Acton, Massachusetts 01720  
(Address of Principal Executive Offices, including Zip Code)**

**04-3523891  
(IRS Employer  
Identification No.)**

**Registrant's telephone number, including area code: (978) 600-7000**

**Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, \$0.001 Par Value Per Share	PODD	The NASDAQ Stock Market, LLC

---

**Item 2.02. Results of Operations and Financial Condition.**

On August 5, 2019, Insulet Corporation (the “Company”) announced its financial results for the second quarter ended June 30, 2019. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated August 5, 2019

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned thereunto duly authorized.

August 5, 2019

INSULET CORPORATION

By: /s/ Shacey Petrovic  
Chief Executive Officer

---

## Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
<u>99.1</u>	<u><a href="#">Press Release dated August 5, 2019</a></u>

## Insulet Reports Second Quarter 2019 Revenue of \$177 Million, an Increase of 43% Year-Over-Year

ACTON, Mass.--(BUSINESS WIRE)--August 5, 2019--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months ended June 30, 2019.

### Second Quarter Financial Highlights:

- Second quarter revenue of \$177.1 million, up 43%, compared to revenue of \$124.3 million in the prior year, exceeds guidance of \$160 to \$165 million
  - Global Omnipod revenue of \$160.8 million, an increase of 51%
    - U.S. Omnipod revenue of \$98.1 million, an increase of 26%
    - International Omnipod revenue of \$62.7 million, an increase of 120%
- Drug Delivery revenue of \$16.3 million, a decrease of 8%
- Gross margin of 65.7%, down 30 basis points
- Operating income of \$7.6 million compared to operating income of \$4.3 million in the prior year
- Net income of \$1.4 million, or \$0.02 per diluted share, compared to a net loss of \$1.7 million, or \$(0.03) per share, in the prior year

### Recent Strategic Highlights:

- Began production in the second quarter on the Company's first U.S. highly-automated manufacturing line
- Presented clinical data on the Omnipod Horizon™ automated insulin delivery system, in which study participants - ages two through six - maintained glucose control in the target range for 73% of time overall and 85% during the overnight period
- Increased coverage for Omnipod DASH™ in the U.S. to approximately half of all covered lives

"We had another strong quarter, as we made excellent progress on our strategic imperatives and delivered continued growth, profitability and financial outperformance," said Shacey Petrovic, President and Chief Executive Officer. "We are investing in innovation in our product portfolio, automated manufacturing, and business model to ensure our customers get improved access to our life-changing technologies across the globe. Our consistently strong financial results give us confidence that we are executing the right strategy to drive strong, sustainable growth over the long-term. We are raising our outlook for full year 2019 and remain on track to meet our 2021 financial targets. We are taking important steps to unlock Insulet's enormous potential and are excited to continue delivering superior growth and returns for investors."

### 2019 Outlook:

- For the year ending December 31, 2019, the Company is raising its revenue guidance to a range of \$700 to \$715 million, representing growth of 24% to 27% (previously 18% to 22%). Revenue ranges by product line are:
  - U.S. Omnipod of \$391 to \$399 million, representing growth of 21% to 23% (previously 16% to 19%)
  - International Omnipod of \$246 to \$250 million, representing growth of 43% to 45% (previously 37% to 42%)
  - Drug Delivery of \$63 to \$66 million, representing a decline of 3% to 8% (previously a decline of 11% to 19%)
- For the quarter ending September 30, 2019, the Company expects revenue in the range of \$174 to \$181 million, representing growth of 15% to 20%. Revenue ranges by product line are:
  - U.S. Omnipod of \$98 to \$102 million, representing growth of 20% to 24%
  - International Omnipod of \$61 to \$63 million, representing growth of 22% to 26%
  - Drug Delivery revenue of \$15 to \$16 million, representing a decline of 15% to 21%

Future results may be affected by changes in ongoing assumptions and judgments, and may also be affected by non-recurring, unusual or unanticipated charges, expenses or gains.

---

**Conference Call:**

Insulet will host a conference call at 4:30 p.m. (Eastern Time) on August 5, 2019 to discuss the financial results and outlook. The link to the live call will be available on the Investor Relations section of the Company's website at <http://investors.insulet.com>, "Events and Presentations", and will be archived for future reference. The call may also be accessed by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode 3268007.

**About Insulet Corporation:**

Insulet Corporation (NASDAQ: PODO), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: [www.insulet.com](http://www.insulet.com) and [www.myomnipod.com](http://www.myomnipod.com).

**Forward-Looking Statements:**

The 2019 financial results contained in this news release are subject to finalization in connection with the preparation of the Company's Form 10-Q for the quarter ended June 30, 2019. This press release contains forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated.

These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Insulet's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with the Company's dependence on its principal product platform, the Omnipod System; risks associated with the Company's ability to design, develop, manufacture and commercialize future products; Insulet's ability to reduce production costs and increase customer orders and manufacturing volumes; adverse changes in general economic conditions; impact of healthcare reform laws; Insulet's ability to raise additional funds in the future on acceptable terms or at all; supply problems or price fluctuations with sole source or third-party suppliers on which Insulet is dependent; the potential establishment of a competitive bid program for conventional insulin pumps; failure by Insulet to retain supplier pricing discounts and achieve satisfactory gross margins; failure by Insulet to retain key suppliers; international business risks; Insulet's inability to effectively operate and grow the Company's business in Europe following the expiration of an agreement with the Company's former European distributor on June 30, 2018; regulatory, commercial and logistics risks associated with the Company selling its products in Europe in light of the uncertainty related to the timing and terms of the separation of the United Kingdom from the European Union (Brexit); Insulet's inability to secure and retain adequate coverage or reimbursement from third-party payors for the Omnipod System or future products and potential adverse changes in reimbursement rates or policies relating to the Omnipod System or future products; failure to retain key payor partners and their members; adverse effects resulting from competition; technological change and product innovation adversely affecting the Company's business; changes to or termination of Insulet's license to incorporate a blood glucose meter into the Omnipod System or its inability to enter into new license or other agreements with respect to the Omnipod System's current or future features; challenges to the future development of our non-insulin drug delivery business; Insulet's ability to protect its intellectual property and other proprietary rights; conflicts with the intellectual property of third parties, including claims that Insulet's current or future products infringe or misappropriate the proprietary rights of others; adverse regulatory or legal actions relating to the Omnipod System or future products; failure of Insulet's contract manufacturers or component suppliers to comply with the U.S. Food and Drug Administration's quality system regulations; the potential violation of the Foreign Corrupt Practices Act or any other international, federal or state laws prohibiting "kickbacks" or protecting the confidentiality of patient health information or other protected personal information, or any challenge to or investigation into Insulet's practices under these laws; product liability lawsuits that may be brought against Insulet, including stemming from off-label use of our product; reduced retention rates of our customer base; unfavorable results of clinical studies relating to the Omnipod System or future products, or the products of Insulet's competitors; future publication of articles or announcement of positions by diabetes associations or other organizations that are unfavorable to the Omnipod System; the concentration of substantially all of Insulet's manufacturing operations at a single location in China and substantially all of Insulet's inventory at a single location in Massachusetts; Insulet's ability to attract and retain personnel; Insulet's ability to manage its growth; fluctuations in quarterly results of operations; risks associated with potential future acquisitions or investments in new businesses; Insulet's ability to generate sufficient cash to service all of its indebtedness; the expansion of Insulet's distribution network; Insulet's ability to successfully maintain effective internal control over financial reporting; the volatility of the trading price of Insulet's common stock; risks related to future sales of its common stock or the conversion of any of the Convertible Senior Notes; potential limitations on Insulet's ability to use its net operating loss carryforwards; anti-takeover provisions in its organizational documents; and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission in February 2019 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

---

**INSULET CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

<b>(Unaudited; in thousands, except per share data)</b>	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
Revenue	\$ 177,136	\$ 124,262	\$ 336,691	\$ 247,840
Cost of revenue	60,718	42,190	113,577	89,953
Gross profit	116,418	82,072	223,114	157,887
Operating expenses:				
Research and development	32,264	18,801	64,218	39,068
Sales and marketing	47,401	36,575	89,017	69,624
General and administrative	29,150	22,371	55,011	44,870
Total operating expenses	108,815	77,747	208,246	153,562
Operating income	7,603	4,325	14,868	4,325
Interest expense and other, net	(5,719)	(5,604)	(8,280)	(11,840)
Income (loss) before income taxes	1,884	(1,279)	6,588	(7,515)
Income tax expense	482	412	808	745
Net income (loss)	\$ 1,402	\$ (1,691)	\$ 5,780	\$ (8,260)
Net income (loss) per share:				
Basic	\$ 0.02	\$ (0.03)	\$ 0.10	\$ (0.14)
Diluted	\$ 0.02	\$ (0.03)	\$ 0.09	\$ (0.14)
Basic weighted-average number of shares outstanding	59,845	58,833	59,601	58,659
Diluted weighted-average number of shares outstanding	61,486	58,833	61,332	58,659

---

**INSULET CORPORATION**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**

<b>(Unaudited; in thousands)</b>	<b>June 30, 2019</b>		<b>December 31, 2018</b>	
<b>ASSETS</b>				
Cash, cash equivalents and short-term investments	\$	309,748	\$	288,946
Accounts receivable and unbilled receivable		78,739		76,672
Inventories		85,109		71,414
Prepaid expenses and other current assets		25,211		24,254
Total current assets		<u>498,807</u>		<u>461,286</u>
Long-term investments		62,677		140,784
Property and equipment, net		334,025		258,379
Goodwill and other intangible assets, net		52,779		50,029
Other assets		29,435		18,266
Total assets		<u>\$ 977,723</u>		<u>\$ 928,744</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>				
Accounts payable	\$	24,752	\$	25,500
Accrued expenses and other current liabilities		81,021		90,157
Total current liabilities		<u>105,773</u>		<u>115,657</u>
Convertible debt, net		607,351		591,978
Other liabilities		14,819		9,010
Total liabilities		<u>727,943</u>		<u>716,645</u>
Stockholders' Equity		249,780		212,099
Total liabilities and stockholders' equity		<u>\$ 977,723</u>		<u>\$ 928,744</u>

## Contacts

***Investor Relations and Media:***

Deborah R. Gordon  
Vice President, Investor Relations and Corporate Communications  
(978) 600-7717 [dgordon@insulet.com](mailto:dgordon@insulet.com)